Immunoway/MCC950（CP-456773）钠/10mg 50mg 100mg/MC1075
市场价：
¥4200.00
美元价：
2100.00
产品分类：
特色ELISA试剂盒
公司分类：
Specialty_ELISA_kits
联系Q Q：
3392242852
电话号码：
4000-520-616
电子邮箱：
info@ebiomall.com
商品介绍
MCC950 (CP-456773) sodium
- Catalog No.：MC1075
- Data Sheet
- MSDS
- Support
- Description
- References ( 0 )
- Protocol
- CasNo：
- 256373-96-3
- MolecularFormula：
- C20H23N2NaO5S
- Purity：
- >98%
- Target：
- NOD-like Receptor (NLR)
- IC50：
- IC50: 7.5 nM (NLRP3, in BMDMs), 8.1 nM (NLRP3, in HMDMs)[1]
- In Vitro：
- MCC950 blocks canonical and non-canonical NLRP3 activation at nanomolar concentrations. MCC950 specifically inhibits NLRP3 but not AIM2, NLRC4 or NLRP1 activation. The effect of MCC950 on NLRP3 inflammasome activation is tested in mouse bone marrow derived macrophages (BMDM) and human monocyte derived macrophages (HMDM). The IC50 of MCC950 in BMDM is approximately 7.5 nM, while in HMDM it has a similar inhibitory capacity (IC50=8.1 nM). MCC950 also dose dependently inhibit IL-1β but not TNF-α secretion.MCC950 specifically blocks caspase-11-directed NLRP3 activation and IL-1β secretion upon stimulation of the non-canonical pathway. NLRC4-stimulated IL-1β and TNF-α secretion (as activated by Salmonella typhimurium) are not inhibited by MCC950 even at a concentration of 10 µM. MCC950 does not inhibit caspase-1 activation or IL-1β processing in response to S. typhimurium. The expression of pro-caspase-1 and pro-IL-1β in cell lysates is not substantially affected by MCC950 treatment[1].
- In Vivo：
- MCC950 reduces Interleukin-1p (IL-1β) production and attenuates the severity of experimental autoimmune encephalomyelitis (EAE), a disease model of multiple sclerosis. Pre-treatment with MCC950 reduces serum concentrations of IL-1β and IL-6 while it does not considerably decrease the amount of TNF-α. Treatment of mice with MCC950 delays the onset and reduced the severity of EAE. Intracellular cytokine staining and FACS analysis of brain mononuclear cells from mice sacrificed on day 22 shows modestly reduced frequencies of IL-17 and IFN-γ producing CD3+ T cells in MCC950 treated mice in comparison with PBS-treated mice. IFN-γ and particularly IL-17 producing cell numbers are also reduced in both the CD4+ and γδ+ sub-populations of CD3+ T cells[1].
- Fields：
- MCC950 (CP-456773) sodium is a potent, selective, small-molecule inhibitor of NLRP3 with IC50 of 7.5 nM in BMDMs.
- Specificity：
- Target:NOD-like Receptor (NLR). Fields: MCC950 (CP-456773) sodium is a potent, selective, small-molecule inhibitor of NLRP3 with IC50 of 7.5 nM in BMDMs.
- Source：
- Rabbit
- Dilution：
- IC50: 7.5 nM (NLRP3, in BMDMs), 8.1 nM (NLRP3, in HMDMs)[1]
- Concentration：
- >98%
- Storage Stability：
- 2 years -20°C Powder, 2 weeks4°C in DMSO,6 months-80°C in DMSO
- Other Name：
- CP-456773 sodium; CRID3 sodium salt; MCC-950 sodium; CP456773 sodium; CRID-3 sodium salt
- MolecularWeight(Da)：
- 426.46
- References：
- [1]. Coll RC, et al. A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat Med. 2015 Mar;21(3):248-55.
- June 19-2018
- WESTERN IMMUNOBLOTTING PROTOCOL
- June 19-2018
- IMMUNOHISTOCHEMISTRY-PARAFFIN PROTOCOL
- June 19-2018
- IMMUNOFLUORESCENCE PROTOCOL
- September 08-2020
- FLOW-CYTOMEYRT-PROTOCOL
- July 13-2018
- CELL-BASED-ELISA-PROTOCOL-FOR-ACETYL-PROTEIN
- July 13-2018
- CELL-BASED-ELISA-PROTOCOL-FOR-PHOSPHO-PROTEIN
- July 13-2018
- CELL-BASED-COLORIMETRIC-ELISA-PROTOCOL-FOR-TOTAL-PROTEIN
- July 13-2018
- Antibody-FAQs
- Products Images
品牌介绍
ImmunowayImmunoWay Biotechnology，我们的使命是帮助世界各地的生命科学研究人员通过更好的产品和服务简化和加速他们的研究。我们专注于开发用于免疫学和细胞学检测的创新和可靠的产品。我们一直是开发高质量ELISA试剂盒，代谢检测试剂盒，抗体和抗体/蛋白质微阵列的先驱，参与癌症，细胞凋亡，细胞生长和信号转导。ImmunoWay Biotechnology，我们的使命是通过更好的产品和服务帮助世界各地的生命科学研究者简化和加速他们的研究。我们专注于开发创新和可靠的产品，用于免疫学和细胞学检测。我们一直是开发涉及癌症，细胞凋亡，细胞生长和信号转导的高质量ELISA试剂盒，代谢测定试剂盒，抗体和抗体/蛋白质微阵列的先驱。
品牌分类
\Elisa试剂盒\
联络我们
